245 related articles for article (PubMed ID: 24407515)
1. Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells.
Sokolosky M; Chappell WH; Stadelman K; Abrams SL; Davis NM; Steelman LS; McCubrey JA
Cell Cycle; 2014; 13(5):820-33. PubMed ID: 24407515
[TBL] [Abstract][Full Text] [Related]
2. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
3. GSK-3β: a key regulator of breast cancer drug resistance.
Martelli AM; Buontempo F; Evangelisti C
Cell Cycle; 2014; 13(5):697-8. PubMed ID: 24526116
[No Abstract] [Full Text] [Related]
4. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
5. Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.
Steelman LS; Navolanic P; Chappell WH; Abrams SL; Wong EW; Martelli AM; Cocco L; Stivala F; Libra M; Nicoletti F; Drobot LB; Franklin RA; McCubrey JA
Cell Cycle; 2011 Sep; 10(17):3003-15. PubMed ID: 21869603
[TBL] [Abstract][Full Text] [Related]
6. Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells.
Taylor JR; Lehmann BD; Chappell WH; Abrams SL; Steelman LS; McCubrey JA
Oncotarget; 2011 Aug; 2(8):610-26. PubMed ID: 21881167
[TBL] [Abstract][Full Text] [Related]
7. GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
Abrams SL; Akula SM; Meher AK; Steelman LS; Gizak A; Duda P; Rakus D; Martelli AM; Ratti S; Cocco L; Montalto G; Cervello M; Ruvolo P; Libra M; Falzone L; Candido S; McCubrey JA
Cells; 2021 Apr; 10(4):. PubMed ID: 33917370
[TBL] [Abstract][Full Text] [Related]
8. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
9. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy.
Sokolosky ML; Stadelman KM; Chappell WH; Abrams SL; Martelli AM; Stivala F; Libra M; Nicoletti F; Drobot LB; Franklin RA; Steelman LS; McCubrey JA
Oncotarget; 2011 Jul; 2(7):538-50. PubMed ID: 21730367
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells.
Kim EY; Kim A; Kim SK; Kim HJ; Chang J; Ahn CM; Chang YS
Respir Res; 2014 Feb; 15(1):26. PubMed ID: 24571487
[TBL] [Abstract][Full Text] [Related]
11. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
12. Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.
Hall BA; Kim TY; Skor MN; Conzen SD
Breast Cancer Res Treat; 2012 Sep; 135(2):469-79. PubMed ID: 22842983
[TBL] [Abstract][Full Text] [Related]
13. GSK-3β at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways.
Vigneron F; Dos Santos P; Lemoine S; Bonnet M; Tariosse L; Couffinhal T; Duplaà C; Jaspard-Vinassa B
Cardiovasc Res; 2011 Apr; 90(1):49-56. PubMed ID: 21233250
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-3646 Contributes to Docetaxel Resistance in Human Breast Cancer Cells by GSK-3β/β-Catenin Signaling Pathway.
Zhang X; Zhong S; Xu Y; Yu D; Ma T; Chen L; Zhao Y; Chen X; Yang S; Wu Y; Tang J; Zhao J
PLoS One; 2016; 11(4):e0153194. PubMed ID: 27045586
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
Leung E; Kim JE; Rewcastle GW; Finlay GJ; Baguley BC
Cancer Biol Ther; 2011 Jun; 11(11):938-46. PubMed ID: 21464613
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of zinc-induced phosphorylation of p70 S6 kinase and glycogen synthase kinase 3beta in SH-SY5Y neuroblastoma cells.
An WL; Bjorkdahl C; Liu R; Cowburn RF; Winblad B; Pei JJ
J Neurochem; 2005 Mar; 92(5):1104-15. PubMed ID: 15715661
[TBL] [Abstract][Full Text] [Related]
18. Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment.
Cao J; Huang W
PLoS One; 2016; 11(2):e0149388. PubMed ID: 26872016
[TBL] [Abstract][Full Text] [Related]
19. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.
Steelman LS; Navolanic PM; Sokolosky ML; Taylor JR; Lehmann BD; Chappell WH; Abrams SL; Wong EW; Stadelman KM; Terrian DM; Leslie NR; Martelli AM; Stivala F; Libra M; Franklin RA; McCubrey JA
Oncogene; 2008 Jul; 27(29):4086-95. PubMed ID: 18332865
[TBL] [Abstract][Full Text] [Related]
20. Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9.
Jiang M; Huang O; Zhang X; Xie Z; Shen A; Liu H; Geng M; Shen K
Molecules; 2013 Jan; 18(1):701-20. PubMed ID: 23299550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
